Plus   Neg

Nektar Posts Positive Topline Data From Human Abuse Potential Study For NKTR-181

Nektar Therapeutics (NKTR) announced Tuesday positive topline results from an oral Human Abuse Potential or HAP study of NKTR-181, a first-in-class opioid analgesic. The company noted that NKTR-181 shows significantly less abuse potential compared to oxycodone.

NKTR-181 is a new chemical entity or NCE that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.

The company noted that NKTR-181 is the first analgesic opioid molecule to exhibit reduction in specific CNS-mediated side effects, like euphoria, through the strategic alteration of brain-entry kinetics. The U.S. Food and Drug Administration has granted the investigational medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain.

Nektar said the NKTR-181 HAP study was designed to confirm and assess the relative oral abuse potential of NKTR-181 at its maximum analgesic or therapeutic dose of 400 mg and at a supratherapeutic dose compared to common therapeutic doses of a Schedule II opioid, oxycodone.

HAP studies are clinical studies that help assess the relative abuse potential of a medicine. The NKTR-181 HAP study was a randomized, double-blind, placebo-controlled, six-sequence crossover study. It evaluated the relative oral abuse potential of NKTR-181 relative to the Schedule II opioid oxycodone in healthy non-dependent recreational drug users experienced in the oral abuse of opioids who can identify drug effects that are relevant to abuse risk assessment.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT